Chondroitin sulfate in therapy osteoarthritis chronic pain patients according to actual clinical recommendations
- Authors: Shavlovskaya O.A.1
-
Affiliations:
- International University of Restorative Medicine
- Issue: Vol 93, No 12 (2021)
- Pages: 1551-1555
- Section: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/96510
- DOI: https://doi.org/10.26442/00403660.2021.12.201241
- ID: 96510
Cite item
Full Text
Abstract
Of undoubted interest is the search for new drugs comparable in effectiveness to nonsteroidal anti-inflammatory drugs (NSAIDs), but with a safer application profile. NSAIDs are characterized by a good analgesic effect due to the modulation of prostaglandin metabolism by inhibition of cyclooxygenase-2. One of the promising directions of pharmacotherapy of degenerative-dystrophic joint lesions is the use of symptom-modifying drugs of delayed action, which include chondroitin sulfate (CS). CS has antiresorptive activity, anti-inflammatory and anti-inflamaging effects. In addition to the direct effect on pain syndrome severity, he also have a modulating level effect of systemic inflammation of cartilage tissue. According to experts of international and Russian societies, pharmaceutical prescription-quality CS is a basic part of the treatment of osteoarthritis. One of the advantages of CS over NSAIDs is the preservation of the effect for 2–4 months after the treatment. Against the background of the use of CS, it is possible to reduce the dose or completely cancel NSAIDs, which helps to reduce the frequency of adverse events associated with their intake. CS has a favorable safety profile, which is important for elderly patients and those with comorbid diseases (cardioprotective effects). CS drugs can be administered per orally, intramuscularly, intra-articularly and in combination with different administration methods. Several clinical trials of CS (Chondrogard), including randomized, were conducted in Russia. The Russia Health Ministry approved the appointment of parenteral CS in clinical guidelines: “Chronic pain in elderly and senile patients” (2020), “Falls in elderly and senile patients”(2020), "Knee osteoarthritis" (2021), "Hip osteoarthritis" (2021).
Full Text
##article.viewOnOriginalSite##About the authors
Olga A. Shavlovskaya
International University of Restorative Medicine
Author for correspondence.
Email: shavlovskaya@1msmu.ru
ORCID iD: 0000-0003-3726-0730
д-р мед. наук, проф. каф. организации медицинской реабилитации и санаторно-курортного лечения
Russian Federation, MoscowReferences
- Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. Lancet. 2020;396(10264):1711-2. doi: 10.1016/S0140-6736(20)32230-3
- Corp N, Mansell G, Stynes S, et al. Evidence-based treatment recommendations for neck and low back pain across Europe: A systematic review of guidelines. Eur J Pain. 2021;25(2):275-95. doi: 10.1002/ejp.1679
- Farra FD, Risio RG, Vismara L, Bergna A. Effectiveness of osteopathic interventions in chronic non-specific low back pain: A systematic review and meta-analysis. Complement Ther Med. 2021;56:102616. doi: 10.1016/j.ctim.2020.102616
- Dougados M. Symptomatic slow-acting drugs for osteoarthritis: what are the facts? Joint Bone Spine. 2006;73(6):606-9. doi: 10.1016/j.jbspin.2006.09.008
- Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-55. doi: 10.1136/ard.2003.011742
- Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797-807. doi: 10.1136/annrheumdis-2017-212662
- Громова ОА, Торшин ИЮ, Лила АМ, и др. Молекулярные механизмы миопротективного действия хондроитина сульфата и глюкозамина сульфата при саркопении. Неврология, нейропсихиатрия, психосоматика. 2019;11(1):117-24 [Gromova OA, Torshin IYu, Lila AM, et al. Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):117-24 (in Russian)]. doi: 10.14412/2074-2711-2019-1-117-124
- Bruyere O, Cooper C, Pelletier JP, et al An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014
- Volpi N. Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci. 2007;96(12):3168-80. doi: 10.1002/jps.20997
- Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008
- Beaudart C, Lengelé L, Leclercq V, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80(18):1947-59. doi: 10.1007/s40265-020-01423-8
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-62. doi: 10.1002/acr.24131
- Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2017;30(2):111-7. doi: 10.1007/s40520-017-0861-1
- Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomized, doubleblind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792
- Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015. doi: 10.1002/14651858.cd005614.pub2
- Honvo G, Bruyere O, Geerinck A, et al. Efficacy of chondroitin sulfate in patients with knee osteoarthritis: a comprehensive metaanalysis exploring inconsistencies in randomized, placebo-controlled trials. Adv Ther. 2019;36(5):1085-99. doi: 10.1007/s12325-019-00921-w
- Shang Q, Yin Y, Zhu L, et al. Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. Int J Biol Macromols. 2016;86:112-8. doi: 10.1016/j.ijbiomac.2016.01.055
- Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. doi: 10.1016/j.joca.2019.06.011
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-99. doi: 10.1136/annrheumdis-2019-216655
- Kloppenburg M, Kroon FPB, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826
- Dabbagh A, MacDermid JC. Appraisal of Clinical Practice Guideline: 2018 update of the EULAR recommendations for the management of hand osteoarthritis. J Physiother. 2021;67(1):68. doi: 10.1016/j.jphys.2020.07.002
- Van den Bosch MHJ. Osteoarthritis year in review 2020: biology. Osteoarthritis Cartilage. 2021;29(2):143-50. doi: 10.1016/j.joca.2020.10.006
- Mazzucchelli R, Rodriguez-Martin S, Garcia-Vadillo A, et al. Risk of acute myocardial infarction among new users of chondroitin sulfate: A nested case-control study. PLoS ONE. 2021;16(7):e0253932. doi: 10.1371/journal.pone.0253932
- Федеральные клинические рекомендации по диагностике и лечению остеоартроза. Общероссийская общественная организация «Ассоциация ревматологов России». 2013. Режим доступа: https://rheumatolog.ru/experts/klinicheskie-rekomendacii. Ссылка активна на 10.10.2021 [Federal clinical guidelines for the diagnosis and treatment of osteoarthritis. All-Russian public organization “Association of rheumatologists of Russia”. 2013. Available at: https://rheumatolog.ru/experts/klinicheskie-rekomendacii. Accessed: 10.10.2021 (in Russian)].
- Клинические рекомендации МЗ РФ «Хроническая боль у пациентов пожилого и старческого возраста». 2020. Режим доступа: https://cr.rosminzdrav.ru/#!/recomend/1033. Ссылка активна на 10.10.2021 [Chronic pain in elderly and senile patients. Russian Federation Health Ministry Clinical recommendations. 2020. Available at: https://cr.rosminzdrav.ru/#!/recomend/1033. Accessed: 10.10.2021 (in Russian)].
- Падения у пациентов пожилого и старческого возраста. Клинические рекомендации Минздрава России. 2020. Режим доступа: https://cr.rosminzdrav.ru/#!/recomend/1030. Ссылка активна на 10.10.2021 [Falls in elderly and senile patients. Federation Health Ministry Clinical recommendations. 2020. Available at: https:// cr.rosminzdrav.ru/#!/recomend/1030. Accessed: 10.10.2021 (in Russian)].
- Гонартроз. Клинические рекомендации Минздрава России. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/667_1. Ссылка активна на 10.10.2021 [Gonarthrosis. Russian Federation Health Ministry Clinical recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/667_1. Accessed: 10.10.2021 (in Russian)].
- Коксартроз. Клинические рекомендации Минздрава России. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/666_1. Ссылка активна на 10.10.2021 [Coxarthrosis. Russian Federation Health Ministry Clinical recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/667_1. Accessed: 10.10.2021 (in Russian)].
- Торшин И.Ю., Лила А.М., Наумов А.В. и др. Метаанализ клинических исследований эффективности лечения остеоартита препаратом Хондрогард. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):388-99 [Torshin IYu, Lila AM, Naumov AV, et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):388-99 (in Russian)]. doi: 10.17749/2070-4909/farmakoekonomika.2020.066
- Алексеева Л.И., Аникин С.Г., Зайцева Е.М., и др. Исследование эффективности, переносимости и безопасности препарата Хондрогард у пациентов с остеоартрозом. РМЖ. 2013;21(32):1624-27. Режим доступа: https://elibrary.ru/item.asp?id=21109420. Ссылка активна на 10.10.2021 [Alekseeva LI, Anikin SG, Zaitseva EM, et al. Investigation of the efficacy, tolerability and safety of the drug Chondrogard in patients with osteoarthritis. Available at: https://elibrary.ru/item.asp?id=21109420. Accessed: 10.10.2021 (in Russian)].
- Торшин И.Ю., Громова О.А., Лила А.М., и др. Толл-подобные рецепторы как компонент патофизиологии остеоартрита: противовоспалительное, анальгетическое и нейропротекторное действие. Неврология, нейропсихиатрия, психосоматика. 2021;13(4):123-9 [Torshin IYu, Gromova OA, Lila AM, et al. Toll-like receptors as a part of osteoarthritis pathophysiology: anti-inflammatory, analgesic and neuroprotective effects. Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):123-9 (in Russian)]. doi: 10.14412/2074-2711-2021-4-123-129
- Громова О.А., Торшин И.Ю., Зайчик Б.Ц., и др. О различиях в стандартизации лекарственных препаратов на основе экстрактов хондроитина сульфата. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2021;14(1):40-52 [Gromova OA, Torshin IYu, Zaychik BTs, et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(1):40-52 (in Russian)]. doi: 10.17749/2070-4909/farmakoekonomika.2021.083
- Громова О.А., Торшин И.Ю., Лила А.М., и др. Стандартизированные формы хондроитина сульфата как патогенетическое средство лечения остеоартрита в контексте постгеномных исследований. Современная ревматология. 2021;15(1):136-43 [Gromova OA, Torshin IYu, Lila AM, et al. Standardised Forms of Chondroitin Sulfate as a Pathogenetic Treatment of Osteoarthritis in the Context of Post-Genomic Studies. Modern Rheumatology Journal. 2021;15(1):136-43 (in Russian)]. doi: 10.14412/1996-7012-2021-1-136-143
- Алексеева Л.И., Шарапова Е.П., Кашеварова Н.Г., и др. Сравнительное исследование эффективности и безопасности препарата Хондрогард® при комбинированном (внутрисуставное и внутримышечное) и внутримышечном введении у пациентов с остеоартритом коленных суставов. Современная ревматология. 2018;12(2):44-9 [Alekseeva LI, Sharapova EP, Kashevarova NG, et al. Comparative study of the efficacy and safety of Chondroguard® during its combined (intra-articular and intramuscular) and intramuscular injection in patients with knee osteoarthritis. Modern Rheumatology Journal. 2018;12(2):44-9 (in Russian)]. DOI:10/14412/1996-7012-2018-2-44-49
- Алексеева Л.И., Кашеварова Н.Г., Таскина Е.А., и др. Эффективность и безопасность внутрисуставного применения комбинации гиалуроната натрия и хондроитина сульфата при остеоартрите коленного сустава: многоцентровое проспективное исследование. Терапевтический архив. 2020;92(5):46-54 [Alekseeva LI, Kashevarova NG, Taskina EA, et al. The efficacy and safety of intra-articular application of a combination of sodium hyaluronate and chondroitin sulfate for osteoarthritis of the knee: a multicenter prospective study. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(5):46-54 (in Russian)]. doi: 10.26442/00403660.2020.05.000631
- Шарапова Е.П., Таскина Е.А., Кашеварова Н.Г., и др. Эффективность хондроитина сульфата у пациентов с остеоартритом коленных и тазобедренных суставов. Современная ревматология. 2021;15(4):120-5 [Sharapova EP, Taskina EA, Kashevarova NG, et al. Efficacy of Chondroitin Sulfate in Patients with Knee and Hip Osteoarthritis. Modern Rheumatology Journal. 2021;15(4):120-5 (in Russian)]. doi: 10.14412/1996-7012-2021-4-120-125
- Сарвилина И.В., Галустян А.Н., Хаджидис А.К., и др. Сравнительный клинико-экономический анализ применения препаратов SYSADOA, содержащих хондроитина сульфат или влияющих на его биосинтез, для лечения пациентов с остеоартрозом коленных суставов II стадии. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019;12(4):255-66 [Sarvilina IV, Galustyan AN, Hadzhidis AK, et al. Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):255-66 (in Russian)]. doi: 10.17749/2070-4909.2019.12.4.255-266
- Лила А.М., Ткачева О.Н., Наумов А.В., и др. Место и роль парентеральной формы хондроитина сульфата в терапии остеоартрита: мультидисциплинарный консенсус. РМЖ. 2021;29(6):68-74. Режим доступа: https://elibrary.ru/item.asp?id=46433906. Ссылка активна на 10.10.2021 [Lila AM, Tkacheva ON, Naumov AV, et al. Place and role of the parenteral form of chondroitin sulfate in the treatment of osteoarthritis: multidisciplinary consensus. RMJ. 2021;29(6):68-74. Available at: https://elibrary.ru/item.asp?id=46433906. Accessed: 10.10.2021 (in Russian)].